Drugs / Autologous human mesenchymal cells (hMSCs)
Autologous human mesenchymal cells (hMSCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00768066 | Aug 2008 → Aug 2012 | disease related to hematopoietic stem cell transplant, left ventricular failure | University of Miami | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous human mesenchymal cells (hMSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00768066 ↗ |
| Known as | mesenchymal stem cells | “The effects of bone-marrow derived mesenchymal stem cells (MSCs) have also been studies clinically.” NCT00768066 ↗ |
| Known as | MSCs | “The study compared injection of MSCs (n=19) with placebo (n = 11) and BMCs (n=19) with placebo (n = 10), with 1 year of follow-up.” PMID 24247587 ↗ Jan 2014 |
| Action | Restore | “designed to replace or repair necrotic, scarred, or dysfunctional myocardium” NCT00768066 ↗ |
| Modality | Cell therapy | “cellular cardiomyoplasty” NCT00768066 ↗ |
| Route | Other | “The injections will be administered transendocardially during cardiac catheterization” NCT00768066 ↗ |